Timeline of Breakthroughs
Scroll right to see some of the groundbreaking advances that HOPP researchers have pioneered in recent years.
—New Gene Function Discovered
Timothy Chan, Ross Levine, Ingo Mellinghoff, and Craig Thompson labs discover that mutations in certain metabolic enzymes cause cancer by changing how DNA is organized in the cell. The results are published in Nature.
—Exceptional Responders Defined
The Michael Berger, Timothy Chan, David Solit, and Barry Taylor labs link a complete response to the drug everolimus (Afinitor®, Zortress®) to mutations in TSC1. The results, reported in Science, launch the National Cancer Institute’s Exceptional Responders Initiative.
—Prostate Cancer Target Discovered
Charles Sawyers and colleagues solve how the glucocorticoid receptor acts as a bypass in antiandrogen-resistant tumors. The results are published in Cell.
—Breast Cancer Drug Resistance Mutations Discovered
The Michael Berger and Sarat Chandarlapaty labs identify mutations in the ligand-binding domain of the estrogen receptor (ESR1). These results are published in Nature Genetics.
—Genomics Predicts Immunotherapy Response
The Timothy Chan and Jedd Wolchok labs, with collaborators, compare and analyze genetic variations among cancer patients to predict who responds best to anti-CTL4A and anti-PD1 immunotherapy, harnessing the patient’s immune system to fight cancer. The results appear in Science and the New England Journal of Medicine.
—Precision Medicine for Breast Cancer
The Sarat Chandarlapaty and Maurizio Scaltriti labs demonstrate that PI3K pathway inhibition upregulates estrogen receptor function. The results appear in Science Translational Medicine.
—Targetable Mutation Identified
The Michael Berger, Timothy Chan, Ping Chi, James Fagin, and Marc Ladanyi labs discover a novel oncogenic form of the ALK protein in melanoma and thyroid carcinomas, generated from an alternative transcription start site. The results are published in Science.
—Targeted Therapy for Leukemia
The Omar Abdel-Wahab lab treats genetically defined myelodysplastic syndrome and acute myeloid leukemia patients by targeting splicesomal proteins. The results are published in Nature Medicine.
—International Data Sharing Launched
AACR Project GENIE, a multi-institutional, international initiative led by Charles Sawyers launches. The phase I includes the release of genomics data from 19,000 cancer patients, linked to clinical outcomes and shared publicly on an open-source platform. The results are published in Cancer Discovery.
—MSK Clinical Sequencing Assay Established
The Michael Berger, Marc Ladanyi, Nikolaus Schultz, David Solit, and Barry Taylor labs, with others at MSK, assemble 10,000 patients for the MSK-IMPACT project, providing publicly accessible data on clinically relevant genomic alterations. The results are published in Nature Medicine.